Quick Answer
PUMA BIOTECHNOLOGY, INC. reported Operating Income of $37.30 million for fiscal year 2025.
PUMA BIOTECHNOLOGY, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $37.30M | +20.5% |
| 2024 | $30.97M | -5.1% |
| 2023 | $32.64M | +37.6% |
| 2022 | $23.72M | +1738.8% |
| 2021 | $1.29M | +104.2% |
| 2020 | -$30.40M | +22.1% |
| 2019 | -$39.05M | +58.8% |
| 2018 | -$94.66M | +67.6% |
| 2017 | -$292.39M | -5.7% |
| 2016 | -$276.60M | -15.1% |
| 2015 | -$240.28M | -68.9% |
| 2014 | -$142.28M | -159.5% |
| 2013 | -$54.83M | +26.3% |
| 2012 | -$74.45M | -633.0% |
| 2011 | -$10.16M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.57M | -56.6% | +44.3% |
| June 30, 2025 | $6.64M | +404.5% | +66.6% |
| March 31, 2025 | $3.98M | +273.3% | -82.0% |
| September 30, 2024 | $22.08M | +157.2% | +1113.3% |
| June 30, 2024 | -$2.18M | -144.5% | +5.2% |
| March 31, 2024 | -$2.30M | -152.7% | -126.8% |
| September 30, 2023 | $8.59M | +258.8% | +75.5% |
| June 30, 2023 | $4.89M | -59.4% | +12.1% |
- PUMA BIOTECHNOLOGY, INC. showed an increase of +20.5% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, PUMA BIOTECHNOLOGY, INC.’s operating income has grown by 467.2% (from -$10.16 million to $37.30 million).
- The most recent figure is from PUMA BIOTECHNOLOGY, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: